Project to redesign clinical trials for neurologic conditions for underserved populations funded with $2.9M grant to UTHealth Houston

(Press-News.org) In an effort to close the gap in neurological outcomes for underserved populations, a UTHealth Houston project funded with $2.9 million from the National Institutes of Health (NIH) will engage community partners to improve the design of clinical trials.

Neurologic conditions including stroke, Parkinson’s disease, and vascular cognitive impairment and dementia contribute to the leading causes of death and disability in the U.S. The goal of the project is to build an infrastructure for community-engaged research interventions for those three neurologic conditions affecting brain health.

“Historically, clinical trials for neurological conditions haven’t consistently or holistically included the voice of underserved communities that shoulder the largest burden of disease,” said Anjail Z. Sharrief, MD, MPH, principal investigator for the trial and professor with the Department of Neurology in McGovern Medical School at UTHealth Houston. “If community input is part of the research plan from the beginning, the clinical trial will more likely include a broader patient population, and research findings and outcomes will be more applicable to the wider range of patients affected by the conditions.”

For example, Sharrief said, designing clinical trials that require patients to come into the clinic during the work week instead of Saturdays limits the ability of lower-wage earners who would lose income by participating. Follow-up televisits instead of in-person visits also make a clinical trial easier for people to join. Including funding for transportation and bilingual research staff would also make it more possible for people from underserved communities to participate.

“We often develop trials for what we, the researchers, are able to do, not what the community is able to do,” Sharrief said.

The project will establish a Brain Health Equity Collaborative to facilitate the academic and community partnerships for clinical trial development. The collaborative will include a community advisory board to review consent forms, assessment questions, and other components of a research trial to ensure they are relatable to a wide range of patients. A community oversight committee will ensure that patient and caregiver voices are being heard and that trials are adhering to protocols for community engagement.

“When you cannot recruit patients from certain communities to participate in a clinical trial, it’s not merely an issue of trust or interest — you’ve made it too hard for them to participate,” Sharrief said. “This is super exciting because it marries our passion for research with our commitment to community engagement and empowerment.”

Community partners include ProSalud, Gulfton Home Community, African American Male Wellness Agency, and the Christopher Pichon II Foundation.

Co-investigators for the trial from the Department of Neurology at McGovern Medical School are Elizabeth Noser, MD, associate professor and James C. Grotta, MD Chair in Neurological Recovery and Stroke; Chigozirim Izeogu, MD, MPH, assistant professor; Mya Schiess, MD, professor, director of Movement Disorders and Neurodegenerative Diseases, and Adriana Blood Distinguished Chair in Neurology; Shivika Chandra, MD, associate professor and chief of neurology at Harris Health Lyndon B. Johnson Hospital; and Kendra Anderson, PhD, assistant professor.

Other co-investigators are Jose-Miguel Yamal, PhD, associate professor of biostatistics at UTHealth Houston School of Public Health; Amy Franklin, PhD, associate professor and associate dean for Student, Faculty, and Community Affairs at McWilliams School of Biomedical Informatics at UTHealth Houston; and Logan Thornton, DrPH, MPH, director of Population Health and Evidence-Based Practice Healthcare Transformation Initiatives at UT Physicians. 

Yamal is a member of The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences. Sharrief, Yamal, Noser, and Anderson are members of the UTHealth Houston Institute for Stroke and Cerebrovascular Diseases.

Funding came from the National Institute of Neurological Disorders and Stroke (1R01NS40001-01), part of the NIH.

 

END